.avif)
Summit Therapeutics Email Format
Biotechnology Research
・
201-500 employees
・
Miami, FL, USA
Summit Therapeutics is a biotechnology research company focused on designing, developing, and commercializing innovative medicinal therapies to improve quality of life and address serious healthcare needs.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@smmttx.com
Company Overview
Industry
Biotechnology Research
Founded
2003
Headquarters
Miami, FL, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Manmeet S. Soni (Chief Operating Officer, Chief Financial Officer and Director), Robert LaCaze (Chief Commercial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Summit Therapeutics?
Summit Therapeutics uses the first.last format on smmttx.com, so Jane Smith would be jane.smith@smmttx.com.
What is Summit Therapeutics' lead drug candidate and what cancer types is it targeting?
Summit Therapeutics' lead candidate is ivonescimab (SMT112), a bispecific antibody targeting both PD-1 and VEGF. It is currently being studied in Phase III trials across non-small cell lung cancer and colorectal cancer under the HARMONi clinical trial program.
How can I find and verify a Summit Therapeutics contact's email address for outreach?
Since Summit Therapeutics follows the first.last@smmttx.com format, you can build most addresses directly. Tools like Clay can help you verify specific contacts at Summit Therapeutics and confirm deliverability before reaching out.
Who leads Summit Therapeutics as Co-CEO?
Summit Therapeutics is co-led by Bob Duggan, who serves as Co-CEO and Chairman, and Dr. Maky Zanganeh, who serves as Co-CEO and President. Manmeet S. Soni serves as Chief Operating Officer and Chief Financial Officer.
Which geographic markets has Summit Therapeutics licensed ivonescimab for?
Summit Therapeutics holds the license for ivonescimab across the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, based on its collaboration and license agreement with Akeso finalized in January 2023.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating